Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume.

Oh J, Henry RG, Pirzkall A, Lu Y, Li X, Catalaa I, Chang S, Dillon WP, Nelson SJ.

J Magn Reson Imaging. 2004 May;19(5):546-54.

PMID:
15112303
2.

Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study.

Laprie A, Catalaa I, Cassol E, McKnight TR, Berchery D, Marre D, Bachaud JM, Berry I, Moyal EC.

Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):773-81. doi: 10.1016/j.ijrobp.2007.10.039.

PMID:
18262090
3.

Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging.

Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, Knopp EA, Zagzag D.

AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98.

4.

3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI.

Pirzkall A, Li X, Oh J, Chang S, Berger MS, Larson DA, Verhey LJ, Dillon WP, Nelson SJ.

Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):126-37.

PMID:
15093908
5.

A preliminary study of the prognostic value of proton magnetic resonance spectroscopic imaging in gamma knife radiosurgery of recurrent malignant gliomas.

Graves EE, Nelson SJ, Vigneron DB, Chin C, Verhey L, McDermott M, Larson D, Sneed PK, Chang S, Prados MD, Lamborn K, Dillon WP.

Neurosurgery. 2000 Feb;46(2):319-26; discussion 326-8.

PMID:
10690720
6.

Multiparametric 3T MR approach to the assessment of cerebral gliomas: tumor extent and malignancy.

Di Costanzo A, Scarabino T, Trojsi F, Giannatempo GM, Popolizio T, Catapano D, Bonavita S, Maggialetti N, Tosetti M, Salvolini U, d'Angelo VA, Tedeschi G.

Neuroradiology. 2006 Sep;48(9):622-31. Epub 2006 Jun 3.

PMID:
16752135
7.

Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.

Crawford FW, Khayal IS, McGue C, Saraswathy S, Pirzkall A, Cha S, Lamborn KR, Chang SM, Berger MS, Nelson SJ.

J Neurooncol. 2009 Feb;91(3):337-51. doi: 10.1007/s11060-008-9719-x. Epub 2008 Nov 15.

8.

Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging.

Zeng QS, Li CF, Liu H, Zhen JH, Feng DC.

Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):151-8. Epub 2007 Feb 7.

PMID:
17289287
9.
10.

Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy.

Preul MC, Caramanos Z, Villemure JG, Shenouda G, LeBlanc R, Langleben A, Arnold DL.

Neurosurgery. 2000 Feb;46(2):306-18.

PMID:
10690719
11.

3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.

Muruganandham M, Clerkin PP, Smith BJ, Anderson CM, Morris A, Capizzano AA, Magnotta V, McGuire SM, Smith MC, Bayouth JE, Buatti JM.

Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):181-9. doi: 10.1016/j.ijrobp.2014.05.014. Epub 2014 Jun 28.

12.

Proton MR spectroscopy of delayed cerebral radiation in monkeys and humans after brachytherapy.

Kinoshita K, Tada E, Matsumoto K, Asari S, Ohmoto T, Itoh T.

AJNR Am J Neuroradiol. 1997 Oct;18(9):1753-61.

13.

[Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors].

Lichy MP, Bachert P, Hamprecht F, Weber MA, Debus J, Schulz-Ertner D, Schlemmer HP, Kauczor HU.

Rofo. 2006 Jun;178(6):627-33. Epub 2006 May 15. German.

PMID:
16703499
14.

Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas.

Li X, Jin H, Lu Y, Oh J, Chang S, Nelson SJ.

NMR Biomed. 2004 Feb;17(1):10-20.

PMID:
15011246
15.

Spectroscopic, diffusion and perfusion magnetic resonance imaging at 3.0 Tesla in the delineation of glioblastomas: preliminary results.

Di Costanzo A, Trojsi F, Giannatempo GM, Vuolo L, Popolizio T, Catapano D, Bonavita S, d'Angelo VA, Tedeschi G, Scarabino T.

J Exp Clin Cancer Res. 2006 Sep;25(3):383-90.

PMID:
17167979
16.

Metabolic imaging of low-grade gliomas with three-dimensional magnetic resonance spectroscopy.

Pirzkall A, Nelson SJ, McKnight TR, Takahashi MM, Li X, Graves EE, Verhey LJ, Wara WW, Larson DA, Sneed PK.

Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1254-64.

PMID:
12128127
17.

Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors.

Calli C, Kitis O, Yunten N, Yurtseven T, Islekel S, Akalin T.

Eur J Radiol. 2006 Jun;58(3):394-403. Epub 2006 Mar 9.

PMID:
16527438
18.

Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.

Deviers A, Ken S, Filleron T, Rowland B, Laruelo A, Catalaa I, Lubrano V, Celsis P, Berry I, Mogicato G, Cohen-Jonathan Moyal E, Laprie A.

Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):385-93. doi: 10.1016/j.ijrobp.2014.06.009. Epub 2014 Aug 4.

PMID:
25104068
19.

Monitoring the effects of BCNU chemotherapy Wafers (Gliadel) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla.

Dyke JP, Sanelli PC, Voss HU, Serventi JV, Stieg PE, Schwartz TH, Ballon D, Shungu DC, Pannullo SC.

J Neurooncol. 2007 Mar;82(1):103-10. Epub 2006 Sep 22.

PMID:
17031552
20.

Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.

Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S, Nelson SJ.

J Neurooncol. 2009 Jan;91(1):69-81. doi: 10.1007/s11060-008-9685-3. Epub 2008 Sep 23.

Supplemental Content

Support Center